A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug prices sent shares of pharmaceuticals companies lower across the ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

The AstraZeneca (LSE: AZN) share price slumped 5% when the market opened on Monday (12 May). Fellow UK pharma giant GSK dipped too, losing 3.5% in early trading. Both regained a bit, with AstraZeneca ...

AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the ...

Trust Specialists Hospital, in partnership with AstraZeneca, has marked World ... to all’, the event highlighted the critical role of symbicort, a combination of formoterol and budesonide ...

May 8 (Reuters) - A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the Medicare health insurance plan the power to negotiate ...

On Thursday, May 8, 2025, a three-judge panel of the Third Circuit affirmed the district court’s rejection of AstraZeneca’s constitutional and regulatory challenge to the Negotiation Program.

The AstraZeneca share price has pulled back in recent months. Dr James Fox explores how the stock compares with pharma peer GSK. When investing, your capital is at risk. The value of your ...

(Alliance News) - AstraZeneca PLC on Friday said it has received positive data from a trial evaluating Imfinzi as a treatment for patients with high-risk non-muscle-invasive bladder cancer.